Monopar Therapeutics (NASDAQ:MNPR) Director Sells $455,585.10 in Stock

Key Points

• Director Kim Tsuchimoto sold 4,090 Monopar Therapeutics shares for $455,585 at an average price of $111.39 under a pre-arranged Rule 10b5-1 trading plan, reducing the position by 35.61% to 7,396 shares.
• MNPR shares rose 0.2% to $113.94, with the stock trading between a 52-week range of $32.77 and $124.82. The company recently reported quarterly EPS of -$0.62, slightly better than the -$0.64 consensus estimate.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and an average price target of $118.67; Barclays, BTIG Research, and Morgan Stanley set targets ranging from $128 to $133.

Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) Director Kim Tsuchimoto sold 4,090 shares of the stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $111.39, for a total value of $455,585.10. Following the completion of the transaction, the director owned 7,396 shares in the company, valued at approximately $823,840.44. The trade was a 35.61% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Monopar Therapeutics Trading Up 0.2%

MNPR stock traded up $0.22 during trading on Thursday, hitting $113.94. 142,825 shares of the company's stock were exchanged, compared to its average volume of 220,179. The business has a 50-day moving average price of $104.63 and a two-hundred day moving average price of $74.34. The stock has a market capitalization of $764.77 million, a price-to-earnings ratio of -52.51 and a beta of 1.47. Monopar Therapeutics Inc. has a 52-week low of $32.77 and a 52-week high of $124.82.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.64) by $0.02. On average, equities research analysts anticipate that Monopar Therapeutics Inc. will post -2.94 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. acquired a new stake in shares of Monopar Therapeutics during the first quarter worth $673,000. Jane Street Group LLC acquired a new position in Monopar Therapeutics in the 1st quarter valued at $377,000. Geode Capital Management LLC raised its position in Monopar Therapeutics by 99.7% during the 2nd quarter. Geode Capital Management LLC now owns 96,919 shares of the company's stock worth $3,468,000 after buying an additional 48,379 shares during the last quarter. JPMorgan Chase & Co. raised its position in Monopar Therapeutics by 1,821.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company's stock worth $69,000 after buying an additional 1,821 shares during the last quarter. Finally, Rhumbline Advisers purchased a new position in Monopar Therapeutics during the 2nd quarter worth $209,000. Institutional investors and hedge funds own 1.83% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on MNPR shares. Barclays reiterated an "overweight" rating and set a $128.00 price target (up from $125.00) on shares of Monopar Therapeutics in a research note on Thursday, August 13th. BTIG Research raised their price objective on Monopar Therapeutics from $117.00 to $133.00 and gave the stock a "buy" rating in a report on Wednesday, August 12th. Morgan Stanley reiterated an "overweight" rating and set a $130.00 target price on shares of Monopar Therapeutics in a research report on Monday, August 17th. Wall Street Zen downgraded Monopar Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday, August 16th. Finally, UBS Group set a $125.00 target price on Monopar Therapeutics in a research report on Thursday, July 23rd. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Monopar Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $118.67.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company's core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company's pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source